Endoscopic Retrograde Cholangiopancreatography (ERCP) has emerged as a vital component in contemporary gastroenterology. The global ERCP market, estimated at USD 2.17 billion in 2024, is anticipated to experience substantial expansion, with a projected Compound Annual Growth Rate (CAGR) of 8.26% from 2025 to 20301. This projected growth trajectory signifies the escalating significance of ERCP in the diagnosis and treatment of biliary and pancreatic pathologies.
The escalating demand for ERCP procedures is largely attributed to the prevalence of gallstones, impacting over one in ten adults in the UK1. In the United States, liver cancer diagnoses are forecasted to reach 41,630 new cases in 2024, while globally, liver cancer results in over 700,000 fatalities annually1. These statistics underscore the critical role of ERCP in managing hepatobiliary and pancreatic diseases.
Advancements in technology are transforming the ERCP domain. Endotherapy devices currently hold a 37.1% market share, while the endoscopes segment is witnessing rapid growth due to innovative breakthroughs1. This transformation in ERCP data reflects the industry’s dedication to improving diagnostic precision and therapeutic outcomes.
The expansion of the ERCP market is further substantiated by regional trends. North America is anticipated to retain its market dominance, driven by cutting-edge diagnostic imaging and medical technology2. The Asia-Pacific region, with a focus on China, India, and Japan, is witnessing an increase in awareness and adoption of ERCP procedures, contributing to market expansion3.
Key Takeaways
- Global ERCP market valued at $2.17 billion in 2024
- Projected 8.26% CAGR from 2025 to 2030
- Endotherapy devices lead with 37.1% market share
- North America dominates the ERCP market
- Rising liver cancer cases drive ERCP demand
- Technological advancements fuel market growth
- Asia-Pacific region shows increasing ERCP adoption
Global ERCP Market Overview
The global Gastrointestinal Endoscopy Devices Market, encompassing ERCP equipment, exhibits considerable growth prospects. In 2023, it was appraised at USD 12,185.1 Million, with forecasts anticipating a valuation of USD 12,891.8 Million in 20244. This upward trajectory in the ercp market size is indicative of a burgeoning demand for minimally invasive diagnostic and therapeutic interventions.
Current Market Valuation
The ERCP market’s current valuation is a direct consequence of an escalating requirement for sophisticated endoscopic methodologies. A study encompassing 2,641 fluoroscopy-guided ERCP procedures across four institutions elucidates the pervasive application of this technique5. The market’s resilience is further underscored by the advent of cutting-edge tools, such as FUJIFILM India’s FushKnife and ClutchCutter, introduced in 20224.
Growth Projections Through 2030
ERCP market trends globally suggest robust growth prospects. The market is anticipated to attain USD 21,413.4 Million by 2033, exhibiting a CAGR of 5.8% from 2024 to 20334. This expansion is propelled by technological innovations, including AI-assisted diagnostics, and a rising patient inclination towards minimally invasive treatments.
Regional Market Distribution
The ERCP market exhibits a diverse regional distribution. An exhaustive analysis spanning North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America reveals disparate market dynamics4. For instance, a European study indicates that ERCP procedures were more prevalent in males (53%), with patient ages spanning from 2 to 100 years5.
| Region | Market Characteristics | Growth Drivers |
|---|---|---|
| North America | Mature market, high adoption of advanced technologies | Aging population, high healthcare expenditure |
| Europe | Diverse market, strong research initiatives | Increasing prevalence of gastrointestinal diseases |
| Asia Pacific | Rapidly growing market, improving healthcare infrastructure | Rising awareness, government initiatives |
| Middle East & Africa | Emerging market, growing investment in healthcare | Increasing medical tourism, improving access to care |
| South & Central America | Developing market, increasing adoption of endoscopic procedures | Rising chronic diseases, improving healthcare policies |
Understanding ERCP Statistics: A Comprehensive Analysis
Endoscopic retrograde cholangiopancreatography (ERCP) has emerged as a critical tool in the diagnosis and treatment of pancreaticobiliary disorders. The global ERCP market, estimated at USD 2.17 billion in 2024, is anticipated to expand at an 8.26% compound annual growth rate (CAGR) from 2025 to 2030. It is projected to reach USD 3.51 billion by 20306.
ERCP procedure statistics indicate a technical success rate of 94% for duodenoscopy and 100% for biliary cannulation7. These high success rates underscore the procedure’s efficacy in addressing a variety of conditions, including gallstones, which affect approximately 6% of the global population6.
The incidence of acute pancreatitis varies globally, ranging from 4.9 to 73.4 per 100,000 individuals, with 35% to 60% of cases attributed to bile duct diseases8. ERCP’s role in managing these conditions is significant, despite the occurrence of complications in 5% to 10% of cases, with a fatality rate between 0.02% and 0.5%8.
ERCP success rates are influenced by several factors, including operator experience and patient characteristics. A study involving 10 trainees demonstrated an improvement in insertion and cannulation times with increasing experience7. This emphasizes the significance of adequate training and experience in achieving superior outcomes.
As the global population ages, with the geriatric population expected to reach 22% by 2050, the demand for ERCP procedures is anticipated to rise6. This demographic shift, coupled with the increasing incidence of liver cancer and other pancreaticobiliary disorders, highlights the escalating relevance of ERCP in contemporary healthcare.
Disease Prevalence and ERCP Demand
The incidence of pancreaticobiliary diseases profoundly impacts the necessity for Endoscopic Retrograde Cholangiopancreatography (ERCP) interventions. Grasping these dynamics is imperative for strategic healthcare planning and resource optimization.
Gallstone Incidence Rates
Gallstone disease persists as a prevalent ERCP indication. A recent investigation approximates global gallstone prevalence at 6%, with a notable increase in females and South American populations. This prevalence accentuates the continuous necessity for ERCP as a diagnostic and therapeutic modality.
Pancreatic Disease Statistics
Pancreatic diseases, most prominently pancreatitis, significantly influence ERCP utilization. The incidence of post-ERCP pancreatitis varies between 5-10%, escalating to 25% in high-risk cohorts9. A Yale-led investigation revealed that 11.4% of patients developed post-ERCP pancreatitis, with lower renalase levels associated with a 12.8% rate of pancreatic inflammation9.
Biliary Disease Frequency
Biliary diseases, including Primary Sclerosing Cholangitis (PSC), frequently necessitate ERCP for management. A study of 201 PSC patients reported that 133 underwent scheduled follow-up ERCPs, whereas 68 received on-demand procedures10. The median transplant-free survival post-initial diagnosis was 17 years for scheduled ERCP patients and 27 years for on-demand ERCP patients10.
These statistics underscore ERCP’s critical role in managing pancreaticobiliary diseases. The ongoing prevalence of ERCP indications and pancreaticobiliary diseases continues to redefine gastroenterological care, underscoring the imperative for continuous research and enhanced diagnostic technologies.
Technological Advancements in ERCP
ERCP technology innovations have transformed endoscopic procedures, significantly improving diagnostic precision and treatment efficacy. High-definition digital imaging systems now capture images with up to 400% the resolution of standard-definition systems, substantially elevating visualization during procedures11.
Advanced endoscopic techniques have been augmented by the integration of wireless capsule endoscopy. This market is anticipated to attain $1.8 billion by 2025, exhibiting a CAGR of 8.2% from 2020 to 202511. These miniature cameras facilitate non-invasive exploration of the gastrointestinal tract, complementing traditional ERCP procedures.
Robotics-assisted endoscopy marks a significant advancement in ERCP technology. The global surgical robotics market is forecasted to reach $15.01 billion by 2027, with studies indicating reduced procedure times and complications compared to traditional methods11. This innovation promises enhanced precision and improved patient outcomes.
Augmented Reality (AR) is another transformative element in ERCP procedures. With the AR market projected to hit $198 billion by 2025, its application in ERCP has demonstrated improved success rates through enhanced navigation11. 3D reconstruction technology provides thorough visualization, aiding in procedural planning and potentially leading to superior patient outcomes.
Single-operator cholangioscopy and remote monitoring technologies are streamlining ERCP procedures, reducing operational costs while elevating safety and efficiency11. These innovations highlight the rapid evolution of ERCP techniques, promising a future of more effective and less invasive gastrointestinal care.
Market Segmentation Analysis
The ERCP market segments exhibit significant shifts in endoscopic device trends. The global endoscopy devices market achieved a valuation of USD 61.06 billion in 2024, with a projected 3.79% CAGR from 2025 to 203012. This expansion is fueled by an aging populace and the escalating incidence of cancer12.
Endotherapy Devices Market Share
Endotherapy devices predominate within the ERCP market segments. The gastrointestinal endoscopy market, valued at USD 15.30 billion in 2023, is forecasted to ascend to USD 23.36 billion by 203113. This segment encompasses ERCP devices, gastrointestinal stents, and balloon dilators, responding to the escalating prevalence of gastrointestinal maladies13.
Endoscopes Segment Growth
Endoscopes hold the largest revenue share in the market. In 2024, the endoscope segment commanded a 41.1% market share12. The disposable endoscope segment is witnessing increased demand, propelled by investments in healthcare infrastructure12.
Visualization Systems Impact
Advancements in visualization systems are revolutionizing ERCP procedures. In April 2024, Medtronic plc unveiled AI software for its GI Genius™ intelligent endoscopy system, augmenting diagnostic prowess13. These innovations are imperative in addressing the estimated 106,180 cases of colon cancer and 44,850 cases of rectal cancer in the U.S. in 202212.
The ERCP market confronts challenges such as elevated operation costs and a shortage of skilled professionals13. Yet, ongoing technological advancements and the introduction of new devices persist in driving market expansion and elevating patient outcomes13.
Healthcare Facility Distribution
The evolution of ERCP service distribution is marked by a significant shift towards outpatient settings, diverging from traditional hospital-centric models. This transformation mirrors broader healthcare delivery trends and patient preference shifts.
Hospital-based ERCP Services
Hospitals continue to play a vital role in ERCP service provision, predominantly for complex procedures. A study of 216 ERCP cases reported a 93% success rate in cannulation, underscoring the expertise found in hospital environments14. The most common indication for ERCP was common bile duct stones, accounting for 75.1% of cases, with 14.9% related to malignancy14.
Outpatient Facility Statistics
Outpatient facilities are increasingly becoming prominent in ERCP service distribution. By 2024, they will hold the largest market share at 53.6%, with the fastest growth rate anticipated in the forthcoming years. This trend highlights the growing preference for ambulatory care settings.
The accessibility to ERCP services profoundly influences treatment options. Patients with high accessibility to ERCP hospitals within a 30-minute drive exhibit 1.53 times higher odds of receiving ERCP treatment compared to those with lower accessibility15. Even within a 45-minute drive, the odds remain favorable at 1.31 times higher15.
Despite the trend towards outpatient care, disparities persist. Black patients are less likely to receive ERCP compared to PTBD, regardless of accessibility, indicating a need for equitable ERCP service distribution across different healthcare settings15.
Regional Market Performance
The global gastrointestinal endoscopy market, encompassing ERCP procedures, exhibits pronounced regional disparities in performance and growth. In 2023, the market valuation reached USD 15.30 billion, with anticipated expansion to USD 23.36 billion by 2031, reflecting a CAGR of 5.64% from 2024 to 203113.
North America held a commanding position in 2023, accounting for a significant share of global revenue. This dominance is attributed to the introduction of novel endoscopic devices and the escalating prevalence of gastrointestinal ailments13. The United States, in particular, boasts the largest patient pool for acute pancreatitis, underscoring its substantial market for treatment16.
ERCP global market trends reveal a paradigm shift towards emerging markets. The expansion of healthcare infrastructure in developing nations is anticipated to unlock growth opportunities for the endoscopy market13. Notwithstanding, regional ERCP statistics underscore challenges, such as a dearth of skilled healthcare professionals, including trained endoscopists, which may impede market growth in specific regions13.
The acute pancreatitis market, intricately linked to ERCP procedures, is forecasted to ascend from US$ 695.9 Million in 2023 to US$ 1.06 Billion by 2034, with a CAGR of 4.82%16. This projected growth trajectory signifies the burgeoning demand for ERCP and associated procedures across diverse regions, mirroring the dynamic evolution of gastrointestinal healthcare on a global scale.
Procedure-specific Insights
Endoscopic retrograde cholangiopancreatography (ERCP) encompasses a variety of procedure types, each designed to address specific medical conditions. This section delves into key statistics and trends within ERCP procedures, focusing on biliary sphincterotomy rates and stenting procedures.
Biliary Sphincterotomy Rates
Biliary sphincterotomy, a prevalent ERCP procedure, commands a substantial market share. In 2024, it comprised 18.7% of the ERCP market, underscoring its critical role in managing biliary disorders.
Stenting Procedure Statistics
Stenting procedures are integral to ERCP interventions. A study involving 661 patients found that 29% received biliary stents during their initial ERCP17. The research also documented a 75% decrease in avoidable stent placements following a quality improvement initiative, leading to cost savings of $C97,50017.
| ERCP Stent Type | Cost per Patient (USD) |
|---|---|
| Fully Covered Metal Stent | 22,729 |
| Uncovered Metal Stent | 24,874 |
| Plastic Stent | 18,701 |
Diagnostic vs. Therapeutic ERCP Ratio
The ratio between diagnostic and therapeutic ERCPs has shifted towards the latter. A study of 162 patients with acute biliary pancreatitis and cholangitis revealed a 94.8% technical success rate for urgent ERCP within 24 hours of admission18. Yet, the timing of ERCP significantly influences outcomes, with procedures performed within 18 hours of symptom onset linked to higher complication rates, such as aspiration pneumonia and post-ERCP hypotension18.
These insights into ERCP procedure types and biliary sphincterotomy statistics highlight the significance of meticulous procedure selection and timing in optimizing patient outcomes and resource utilization in ERCP practice.
Age Demographics and ERCP Utilization
The ercp age distribution exhibits marked variability across diverse patient cohorts. A detailed examination of 1124 ERCP procedures revealed a median age of 13.2 years for patients with pre-ERCP acute pancreatitis, marginally higher at 13.5 years for those without such antecedent conditions19. This disparity underlines the imperative of age-specific considerations in ERCP application.
Geriatric ERCP statistics unveil intriguing patterns. An extensive analysis of 860,679 inpatient ERCPs disclosed a mean patient age of 61.62 years, with a gender distribution skewed towards females at 57%20. This highlights a pronounced ERCP utilization trend in the elderly, necessitating age-appropriate care modalities.
The distribution of ERCP difficulty across age cohorts offers profound insights. Among patients with pre-ERCP acute pancreatitis, 53.6% of procedures were classified as high difficulty (Grade 3-4), contrasting with 36% in those without such antecedent conditions19. This disparity highlights the inherent complexities in geriatric ERCP interventions.
| Age Group | ERCP Procedures | High Difficulty (%) |
|---|---|---|
| Pre-ERCP AP | 194 | 53.6% |
| No Pre-ERCP AP | 930 | 36.0% |
In specific patient cohorts, such as those with cystic fibrosis (CF), the mean ERCP age was slightly lower at 60.62 years20. This finding emphasizes the necessity for customized management strategies in ERCP across various age groups and medical conditions.
Grasping the ercp age distribution is vital for healthcare professionals to enhance patient care and optimize resource allocation. As the global demographic shifts towards an older population, these geriatric ERCP statistics will gain increasing significance in guiding clinical practices and health policy formulations.
Investment and Research Trends
The ERCP market is witnessing a notable expansion, with the global market size anticipated to reach USD 2.17 billion in 2024, and projected to escalate to USD 3.51 billion by 2030, exhibiting a CAGR of 8.26% from 2025 to 20306. This upward trajectory is propelled by the escalating prevalence of diseases and the technological innovations within the sector.
Research and Development Spending
Investment in ERCP research trends is evident through strategic partnerships and innovative developments. Olympus has entered into a partnership with EndoClot Plus to enhance accessibility to advanced gastrointestinal bleeding treatments6. A groundbreaking study by the Optica Publishing Group has unveiled the development of a photoacoustic imaging endoscope probe, fitting into a 0.6 mm diameter medical needle, marking a significant leap in endoscopy innovation metrics6.
Clinical Trial Statistics
Recent clinical trials have compared EUS-BD and ERCP techniques. A meta-analysis of 7 studies involving 1245 patients revealed that EUS-BD exhibited a higher technical success rate (92%) compared to ERCP (85%), with both methods achieving similar clinical success rates of about 89%21. The incidence of pancreatitis was significantly lower in EUS-BD (2%) compared to ERCP (10%)21.
Innovation Metrics
The gastrointestinal endoscopy devices market is projected to grow from USD 12,891.8 Million in 2024 to USD 21,413.4 Million by 2033, with a CAGR of 5.8%4. This growth is fueled by advancements in telehealth, AI-assisted diagnostics, and remote monitoring capabilities, which are elevating procedural efficiency and patient safety4. The transition towards minimally invasive procedures is accelerating the adoption of gastrointestinal endoscopy devices, promising reduced infection risks and improved patient outcomes4.
Key Market Players and Share Distribution
The ERCP market leaders are orchestrating a transformative evolution within the realm of endoscopic interventions. In 2023, the valuation of the endotherapy devices market, a cornerstone for ERCP, ascended to USD 4.8 billion, with forecasts predicting a formidable CAGR of 7.8% through 203222. This exponential growth mirrors the burgeoning demand for sophisticated ERCP technologies and the expanding demographic necessitating these interventions.
Preeminent entities within the endoscopy company market share are spearheading innovation and market expansion. The global endoscopy devices market, which encompasses ERCP equipment, attained a valuation of USD 61.06 billion in 2024, with projections indicating a CAGR of 3.79% until 203012. This trajectory signifies the substantial investments in research and development by industry stalwarts.
Industry leaders are engaging in strategic acquisitions to fortify their market dominance. For example, Boston Scientific Corporation’s acquisition of Apollo Endosurgery for USD 615 million exemplifies the competitive dynamics of the sector and the imperative for portfolio augmentation among ERCP market leaders.
The market is witnessing a paradigm shift towards specialized technologies, with the gastrointestinal devices & accessories segment commanding a 56.6% market share in 202322. This specialization is imperative for ERCP procedures, which necessitate high-precision instruments for optimal patient outcomes.
Regional markets exhibit disparate growth trajectories. North America’s endotherapy devices market was valued at USD 2.2 billion in 2023, with the U.S. market anticipated to reach USD 4 billion by the end of the forecast period22. These figures underscore the substantial endoscopy company market share concentrated in this region.
As the industry progresses, the emphasis on disposable endoscopes is intensifying, driven by infection control imperatives. This trend is reconfiguring product offerings and market strategies among the vanguard ERCP device manufacturers, heralding a transformation in market dynamics and share distribution in forthcoming years.
Conclusion
The ERCP future outlook appears auspicious, with endoscopy market projections forecasting continued expansion. Recent investigations have shed light on ERCP procedures and their outcomes. An exhaustive examination of 172 ERCP candidates disclosed a mean age of 53.77 years, with a slight male predominance (57%). The most prevalent indication was common bile duct stones (36%), while complications during and post-ERCP were relatively low at 2.3% and 2.9%, respectively23.
Despite the progress made, ERCP failure rates persist between 5-20% even among seasoned practitioners. Post-ERCP pancreatitis (PEP) remains a pressing concern, with an incidence rate of 9.7% and an associated mortality rate of 0.7%24. These statistics underscore the imperative for ongoing research and the development of improved techniques to elevate ERCP success rates and patient safety.
Papilla morphology significantly influences ERCP outcomes. Type IV papillae present the highest rate of difficult cannulation at 41%, compared to 26% for Type I. Interestingly, Type II papillae show the highest incidence of post-ERCP pancreatitis at 11%24. These findings underscore the significance of tailored approaches based on individual patient anatomy to optimize ERCP procedures and minimize complications.
As the endoscopy market continues to evolve, addressing these challenges will be critical. Future advancements in ERCP techniques and technologies will likely focus on reducing complication rates, improving cannulation success, and elevating overall patient outcomes. Continued research and innovation in this field will be essential to shape the ERCP future outlook and drive progress in gastrointestinal endoscopy.
FAQ
What is ERCP and why is it significant in gastroenterology?
What is the current global market size for ERCP?
What are the growth projections for the ERCP market through 2030?
What are the typical success rates for ERCP procedures?
How prevalent are gallstones, and how does this affect ERCP demand?
What recent technological advancements have improved ERCP procedures?
How is the ERCP market segmented?
What is the distribution of ERCP services between hospitals and outpatient facilities?
What is the ratio of diagnostic to therapeutic ERCPs?
How does age affect ERCP utilization and outcomes?
What are the current trends in ERCP-related research and development?
Who are the key players in the ERCP market?
Source Links
- Endoscopic Retrograde Cholangiopancreatography Market Report, 2030 – https://www.grandviewresearch.com/industry-analysis/endoscopic-retrograde-cholangiopancreatography-ercp-market-report
- Endoscopic Retrograde Cholangiopancreatography Market Share, Size & Growth Report | 2032 – https://www.skyquestt.com/report/endoscopic-retrograde-cholangiopancreatography-market/market-size
- Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Targets US$ 2.8 Billion Milesto – https://www.pharmiweb.com/press-release/2024-02-29/endoscopic-retrograde-cholangiopancreatography-ercp-devices-market-targets-us-28-billion-milesto
- [Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 21,413.4 Million by 2033 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) – https://www.globenewswire.com/news-release/2024/12/10/2994768/0/en/Latest-Global-Gastrointestinal-Endoscopy-Devices-Market-Size-Share-Worth-USD-21-413-4-Million-by-2033-at-a-5-8-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Fo.html
- Assessing Patient Radiation Exposure in Endoscopic Retrograde Cholangiopancreatography: A Multicenter Retrospective Analysis of Procedural Complexity and Clinical Factors – https://www.mdpi.com/2075-4418/14/6/656
- Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis, 2025-2030 – Gallstone Prevalence Expected to Surge, Boosting ERCP Adoption – https://www.globenewswire.com/news-release/2025/01/29/3017412/0/en/Endoscopic-Retrograde-Cholangiopancreatography-ERCP-Market-Analysis-2025-2030-Gallstone-Prevalence-Expected-to-Surge-Boosting-ERCP-Adoption.html
- Endoscopic retrograde cholangiopancreatography training using a silicone simulator fabricated using a 3D printing technique (with videos) – Scientific Reports – https://www.nature.com/articles/s41598-025-86755-9
- Meta-analysis of the effectiveness of early endoscopic treatment of Acute biliary pancreatitis based on lightweight deep learning model – BMC Gastroenterology – https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03361-1
- Renalase May Predict Post-ERCP Pancreatitis – https://medicine.yale.edu/news-article/renalase-post-ercp-pancreatitis/
- Long-term impact of scheduled regular endoscopic interventions for patients with primary sclerosing cholangitis – https://pmc.ncbi.nlm.nih.gov/articles/PMC11371311/
- HealixHospitals – https://www.healixhospitals.com/blogs/innovations-in-ercp-technology:-advancements-and-future-trends
- Endoscopy Devices Market Size And Share Report, 2030 – https://www.grandviewresearch.com/industry-analysis/endoscopy-devices-market
- Gastrointestinal Endoscopy Market Research Study 2024-2031 – https://www.insightaceanalytic.com/report/global-gastrointestinal-endoscopy-market-/1361
- Clinical Profiles and Outcomes of Patients Undergoing Endoscopic Retrograde Cholangiopancreatography in a Tertiary Care Center – https://pmc.ncbi.nlm.nih.gov/articles/PMC10977615/
- Accessibility to ERCP‐performing hospitals among patients with pancreatic cancer living in SEER regions – https://pmc.ncbi.nlm.nih.gov/articles/PMC10891451/
- Acute Pancreatitis Market Report 2024-2034: Epidemiology, Industry Trends, Share, Size, Opportunities and Forecasts – https://finance.yahoo.com/news/acute-pancreatitis-market-report-2024-090900853.html
- Optimising the indications for biliary stent placement during endoscopic retrograde cholangiopancreatography: a quality improvement initiative to enhance patient care and reduce healthcare resource utilisation – https://pmc.ncbi.nlm.nih.gov/articles/PMC11340697/
- Increased ERCP-related adverse event from premature urgent ERCP following symptom onset in acute biliary pancreatitis with cholangitis – Scientific Reports – https://www.nature.com/articles/s41598-024-64644-x
- Pediatric ERCP in the Setting of Acute Pancreatitis: A Secondary Analysis of an International Multicenter Cohort Study – https://pmc.ncbi.nlm.nih.gov/articles/PMC10198832/
- ERCP Safe for Clearing Biliary Tract in Cystic Fibrosis – https://www.gastroenterologyadvisor.com/news/ercp-safe-for-clearing-biliary-tract-in-cystic-fibrosis/
- Comparative efficacy of endoscopic ultrasound-guided biliary drainage versus endoscopic retrograde cholangiopancreatography as first-line palliation in malignant distal biliary obstruction: a systematic review and meta-analysis – https://pmc.ncbi.nlm.nih.gov/articles/PMC11372544/
- Endotherapy Devices Market Share, Statistics Report 2024-2032 – https://www.gminsights.com/industry-analysis/endotherapy-devices-market
- Predicting acute complications in endoscopic retrograde cholangiopancreatography based on the severity and onset of post-procedural pain – Egyptian Liver Journal – https://eglj.springeropen.com/articles/10.1186/s43066-024-00355-2
- Morphology of the papilla can predict procedural safety and efficacy of ERCP—a systematic review and meta-analysis – Scientific Reports – https://www.nature.com/articles/s41598-024-57758-9